Dr. Jeanette Wood Has Joined Nuevolution as Director and Senior Scientific Advisor to the Board of Directors
Copenhagen, Denmark, September 21, 2015 / B3C newswire / -- Nuevolution A/S, a leading small molecule drug discovery company, today announced that Dr. Jeanette Wood has joined Nuevolution's board of directors and will furthermore serve as scientific advisor to the board.
"We are very pleased that Dr. Jeanette Wood has accepted to join us as Director and Scientific Advisor," said Alex Gouliaev, CEO of Nuevolution A/S and continued "Jeanette has extensive experience in all aspects of drug discovery from target validation, lead optimisation, biomarker development, through to translational research in support of clinical trials as well as experience in multiple therapeutic areas. Her extensive expertise and experience will strongly support Nuevolution in successfully developing its pipeline within oncology, inflammation and immuno-oncology."
Jeanette Wood, Ph.D. is presently CSO at Swiss-based biotech company Genkyotex. In this role she is responsible for the NOX enzyme platform, and the discovery and early development portfolio.
Born and educated in New Zealand (PhD in Pharmacology from University of Otago, Dundein, New Zealand), Jeanette began her drug discovery career in the cardiovascular area in Ciba-Geigy in Switzerland. Early research was focused on innovative small molecule drugs targeting the renin-angiotensin system and later, in Novartis, on anti-angiogenesis therapies for cancer and inflammatory diseases. In both the cardiovascular and cancer areas, Jeanette successfully led various global drug discovery teams and research groups and she played a major role in the discovery and/or profiling of several marketed drugs and compounds in the Novartis development portfolio. Jeanette left Novartis to join Singapore-based S*BIO, as Head of Biology.
Under her leadership, 6 novel compounds targeting HDAC, JAK2, CDK, mTOR and PI3K were discovered and selected for development as new therapies for cancer and autoimmune diseases, of which 4 programs entered and are still progressing in clinical development. Before joining Genkyotex, Jeanette held a senior management positions at AstraZeneca where she was responsible for the early discovery portfolio within oncology including biology, chemistry and DMPK functions to support both the research and development portfolios.
Jeanette is author of numerous scientific publications and patents and has served as an Adjunct Professors at Universities in Basel, Singapore and Korea.
Nuevolution's Board of Directors is composed as follows:
- Stig Løkke Pedersen, Chairman of the Board.
- Viktor Drvota, Director, SEB Venture Capital, Head of Investment Area, Life Science.
- Søren Lemonius, Director, Partner, Sunstone Capital.
- Lars Henriksson, Director, Investment Manager, Industrifonden.
- Professor Dr. Jutta Heim, Director, Senior Scientific Advisor to the Board
- Dr. Jeanette Wood, Director, Senior Scientific Advisor to the Board
- Stefan Olofsson, Observer, SEB Venture Capital Investment Manager, Life Science and Technology
Stig Løkke Pedersen, Chairman of Nuevolution A/S said: "Nuevolution has successfully developed and commercialized its Chemetics® technology to a very advanced level, and is progressing its own programs within oncology, inflammation and immuno-oncology. We are convinced that Jeanette's expertise in drug discovery and drug development will add further important expertise to the Board of Directors."
"I am excited to join Nuevolution as Board Member and Scientific Advisor", Jeanette Wood commented. "Nuevolution has a very powerful proprietary discovery engine that can be applied to attractive but difficult drug targets in areas of high unmet medical need. My experience and competencies really complement very strong management and board teams. I look forward to helping advance some very novel drug candidates as well as the commercial success of this innovative company."
About Nuevolution
Nuevolution is a leading small molecule drug discovery biotech company founded in 2001, and based in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
The company has developed its proprietary drug discovery platform Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery platform for both identification and optimization of hit to candidate compounds. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimization of these, facilitating the identification of potent drug leads at unprecedented speed and scale.
Nuevolution has also entered into agreements with Merck & Co. (MSD), Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis, Boehringer Ingelheim and Cancer Research Technology, where Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered into technology licensing agreements with Nuevolution. Nuevolution has also entered a scientific collaboration by and between Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals and Nuevolution.
Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital and Industrifonden.
Contacts
Nuevolution A/S
Alex Haahr Gouliaev, CEO
Phone: +45 7020 0987
[email protected]
Stig Løkke Pedersen, Chairman
Phone: +45 4086 4151
[email protected]